Back to results
US 11,441,126 B2Granted
Platform for the induction and maintenance of ground state pluripotency
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Megan Robinson, Ramzey Abujarour
Life of this patent
Estimating the term…
Abstract
The invention provides compositions and methods for manufacturing pluripotent cells. In particular, the invention provides improved culture platforms for manufacturing pluripotent cells with ground state pluripotency.
Claims21
A method of reprogramming human non-pluripotent cells comprising:
- introducing into the non-pluripotent cell a plurality of polypeptides, or one or more polynucleotides encoding said polypeptides, wherein the plurality of polypeptides comprises:
- (i) a first combination comprising octamer-binding transcription factor 4 (OCT4), and one or more of sex determining region Y-Box-2 (SOX2), NANOG, Kruppel-like factor (KLF), LIN28, cellular MYC (C-MYC), ES cell associated transcript 1 (ECAT1), Undifferentiated Embryonic Cell Transcription Factor 1 (UTF1), Estrogen Related Receptor Beta (ESRRB), and Simian virus 40 large T antigen (SV40LT);
- and
- (ii) a second combination comprising two or more polypeptides selected from the group consisting of hES cells related gene (HESRG), Cadherin 1 (CDH1), teratocarcinoma-derived growth factor 1 (TDGF1), Developmental Pluripotency Associated 4 (DPPA4), Zinc finger of the cerebellum protein family member 3 (ZIC3), and LINE-1 type transposase domain-containing protein 1 (L1TD1);
- thereby reprogramming the non-pluripotent cells to produce pluripotent cells, wherein the reprogramming is at an increased efficiency as compared to reprogramming with the first combination without the second combination.
2 more elements
A method of reprogramming human non-pluripotent cells comprising:
- (a) introducing into the non-pluripotent cells one or more polynucleotides encoding OCT4, and one or more of KLF, SOX2, C-MYC, NANOG, ECAT1, UTF1, and ESRRB;
- and
- (b) introducing into the non-pluripotent cells one or more polynucleotides encoding two or more polypeptides selected from the group consisting of L1TD1, TDGF1, DPPA4, CDH1, ZIC3, and HESRG;
- thereby obtaining pluripotent cells, wherein the reprogramming is at an increased efficiency as compared to reprogramming with the one or more polynucleotides of (a) without the one or more polynucleotides of (b).
1 more element
A method of reprogramming human non-pluripotent cells using Sendai virus comprising:
- (a) introducing into the non-pluripotent cells with Sendai virus one or more polynucleotides encoding OCT4, and one or more of KLF, SOX2, C-MYC, NANOG, ECAT1, UTF1, and ESRRB;
- and
- (b) introducing into the non-pluripotent cells with Sendai virus one or more polynucleotides encoding two or more polypeptides selected from the group consisting of L1TD1, TDGF1, DPPA4, CDH1, ZIC3, and HESRG;
- thereby obtaining a pluripotent cells, wherein the reprogramming is at an increased efficiency as compared to reprogramming with the one or more polynucleotides of (a) without the one or more polynucleotides of (b).
1 more element
Dependencies are inferred from the claim text.